Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Cellectar Biosciences announced that a subset of data from their CLOVER WaM clinical trial involving iopofosine I-131 was accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The data focuses on relapsed/refractory Waldenström macroglobulinemia (WM) patients who have progressed after treatment with BTK inhibit…